CA
HRTX icon

Clearstead Advisors’s Heron Therapeutics HRTX Stock Holding History

Clearstead Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49K Buy
3,498
+298
+9% +$239 ﹤0.01% 2581
2026
Q1 		$2.56K Hold
3,200
– – ﹤0.01% 1851
2025
Q4 		$4.16K Sell
3,200
-1,561
-33% -$1.93K ﹤0.01% 2048
2025
Q3 		$6K Buy
4,761
+1,561
+49% +$2.48K ﹤0.01% 2088
2025
Q2 		$6.62K Hold
3,200
– – ﹤0.01% 2024
2025
Q1 		$7.04K Hold
3,200
– – ﹤0.01% 1692
2024
Q4 		$4.9K Hold
3,200
– – ﹤0.01% 1722
2024
Q3 		$6.37K Hold
3,200
– – ﹤0.01% 1677
2024
Q2 		$11.2K Hold
3,200
– – ﹤0.01% 1528
2024
Q1 		$9.01K Hold
3,200
– – ﹤0.01% 1070
2023
Q4 		$5.44K Hold
3,200
– – ﹤0.01% 1155
2023
Q3 		$3.3K Hold
3,200
– – ﹤0.01% 1140
2023
Q2 		$3.71K Buy
3,200
+1,800
+129% +$3.21K ﹤0.01% 1078
2023
Q1 		$2.11K Hold
1,400
– – ﹤0.01% 1128
2022
Q4 		$3.5K Hold
1,400
– – ﹤0.01% 1023
2022
Q3 		$6K Hold
1,400
– – ﹤0.01% 952
2022
Q2 		$4K Hold
1,400
– – ﹤0.01% 1029
2022
Q1 		$8K Hold
1,400
– – ﹤0.01% 1016
2021
Q4 		$13K Hold
1,400
– – ﹤0.01% 894
2021
Q3 		$15K Hold
1,400
– – ﹤0.01% 881
2021
Q2 		$22K Hold
1,400
– – ﹤0.01% 693
2021
Q1 		$23K Hold
1,400
– – ﹤0.01% 651
2020
Q4 		$30K Hold
1,400
– – ﹤0.01% 575
2020
Q3 		$21K Hold
1,400
– – ﹤0.01% 578
2020
Q2 		$21K Hold
1,400
– – ﹤0.01% 521
2020
Q1 		$16K Buy
+1,400
New +$26.3K ﹤0.01% 525

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Clearstead Advisors's HRTX Position: Q2 2026 in Review

Clearstead Advisors increased its Heron Therapeutics (HRTX) stake by 9.3% in Q2 2026, buying an estimated $239 and bringing the position to 3,498 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #2581.

Clearstead Advisors first reported a position in HRTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $30K in Q4 2020. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Clearstead Advisors held 3,498 shares of Heron Therapeutics worth $1.49K as of Q2 2026.
  • Clearstead Advisors bought 298 Heron Therapeutics shares in Q2 2026, an estimated $239.
  • Heron Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2581 holding.
  • Clearstead Advisors first reported a position in Heron Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Clearstead Advisors's Heron Therapeutics position peaked at $30K in Q4 2020.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.